Abordaje integral del riesgo cardiovascular residual: estrategias farmacológicas combinadas

URL canonica: https://calculadoras.nmn.mx/articulo/abordaje-integral-riesgo-cardiovascular-residual-estrategias-farmacologicas-combinadas

Tipo: ARTICULO

Areas terapeuticas

  • Cardiometabolico

Padecimientos

  • Hipertensión arterial sistémica
  • Dislipidemia mixta
  • Aterosclerosis

Contenido

El riesgo cardiovascular residual (RCVR) representa el riesgo persistente de eventos ateroscleróticos a pesar de alcanzar los objetivos terapéuticos para los factores de riesgo clásicos, como la presión arterial, la glucemia y, crucialmente, el colesterol unido a lipoproteínas de baja densidad (cLDL). 1, 2

Se estima que aproximadamente el 70% de los pacientes tratados de manera óptima con estatinas continúan teniendo un riesgo sustancial de eventos cardiovasculares adversos mayores (MACE, por sus siglas en inglés).2

Referencias

  1. Ponte-Negretti CI, , et al. Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan- American College of Endothelium (PACE). Arch Cardiol Mex. 2022;92(1):99–112.
  2. Reijnders E, van der Laarse A, Jukema JW, et al. High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine. Front Cardiovasc Med. 2023;10:1264319.
  3. Ferri N, Ruscica M, Santos RD, et al. Fixed Combination for the Treatment of Dyslipidaemia. Curr Atheroscler Rep. 2023;25:691–699.
  4. Guijarro C, Diaz A, Moreno E, et al. Eficiencia de las combinaciones a dosis fija de estatina ezetimiba en el tratamiento de la hipercolesterolemia. Clin Investig Arterioscler. 2025;37:500753.
  5. Wei Z, Wang F, Zhang L, et al. Clinical Efficacy of Ezetimibe Combined with Rosuvastatin in the Treatment of Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Therapy. Br J Hosp Med. 2024.
  6. Banach M, Surma S, Bielecka-Dąbrowa A, et al. Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025. Arch Med Sci. 2025;21(1):1–15.
  7. Alagona Jr P. Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vascular health and risk management. 2010:351-62.